Research2 sources
Erasca data add to pressure facing Revolution’s breakthrough cancer drug
BioPharma Dive · By Jonathan Gardner ·
The Brief · written from 2 sources
- Erasca reported data on its KRAS-targeted drug in pancreatic cancer, adding pressure on Revolution Medicines' drug Rasonque, according to BioPharma Dive.
- BioPharma Dive says Rasonque is already off to one of the best oncology launches in history, but certain limitations leave room for rivals such as Erasca, which is nearing the start of a Phase 3 trial.
- New Phase I/II results reported by Medical Xpress show daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with metastatic pancreatic cancer.
Why it matters
Competition is forming around KRAS-targeted treatment for pancreatic cancer, and the limitations of the leading drug may shape which approaches reach later-stage trials.
Who’s affected
- oncologists and pancreatic cancer researchers
- patients with metastatic pancreatic cancer
- #pancreatic cancer
- #kras
- #daraxonrasib
- #oncology drugs
- #clinical trials
Rasonque is already off to one of the best oncology launches in history. But certain limitations leave an opportunity that companies like Erasca — which is nearing the start of a Phase 3 trial — may be able to exploit.
Timeline
Full coverage · 2 sources
- 2h ago ↗
Medical Xpress - latest medical and health news stories
Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy - 5h ago ↗
BioPharma Dive - Latest News
Erasca data add to pressure facing Revolution’s breakthrough cancer drug